BIOGEN INC. — Director's Dealing 2023

Feb 22, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2023-02-17

Reporting Person: Murphy Nicole (Head of Pharm Ops and Tech)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-17	Common Stock	M	480	—	Acquired	5579.2903	Direct
2023-02-17	Common Stock	F	233	$278.38	Disposed	5099.2903	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-17	Restricted Stock Unit	$0	M	480	Disposed	2024-02-18	Common Stock (480)	Direct
2023-02-17	Restricted Stock Unit	$0	J	426	Disposed	2024-02-18	Common Stock (426)	Direct

Footnotes

F1: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.